EP4164689A4 - Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1 - Google Patents
Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1 Download PDFInfo
- Publication number
- EP4164689A4 EP4164689A4 EP21821720.6A EP21821720A EP4164689A4 EP 4164689 A4 EP4164689 A4 EP 4164689A4 EP 21821720 A EP21821720 A EP 21821720A EP 4164689 A4 EP4164689 A4 EP 4164689A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- diabetes
- compositions
- methods
- preventing type
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037968P | 2020-06-11 | 2020-06-11 | |
| TW110102871A TWI889747B (zh) | 2020-06-11 | 2021-01-26 | 用於預防第1型糖尿病的方法及組成物 |
| US202163192242P | 2021-05-24 | 2021-05-24 | |
| PCT/US2021/037039 WO2021252917A2 (en) | 2020-06-11 | 2021-06-11 | Methods and compositions for preventing type 1 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4164689A2 EP4164689A2 (de) | 2023-04-19 |
| EP4164689A4 true EP4164689A4 (de) | 2024-07-24 |
Family
ID=85557394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21821720.6A Pending EP4164689A4 (de) | 2020-06-11 | 2021-06-11 | Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1 |
Country Status (1)
| Country | Link |
|---|---|
| EP (1) | EP4164689A4 (de) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) * | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
-
2021
- 2021-06-11 EP EP21821720.6A patent/EP4164689A4/de active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) * | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Non-Patent Citations (1)
| Title |
|---|
| KEVAN C. HEROLD ET AL: "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 7, 15 August 2019 (2019-08-15), US, pages 603 - 613, XP055760445, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1902226 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4164689A2 (de) | 2023-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4247376A4 (de) | Verbindungen, zusammensetzungen und verfahren | |
| AU2023275531B2 (en) | Methods and compositions for preventing or delaying type 1 diabetes | |
| EP4370110A4 (de) | Verbindungen, zusammensetzungen und verfahren | |
| EP4025556A4 (de) | Lipidverbindung und ihre zusammensetzung | |
| HK40095886A (en) | Methods and compositions for preventing type 1 diabetes | |
| EP4164689A4 (de) | Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1 | |
| EP4054558A4 (de) | Verfahren und zusammensetzungen zur behandlung von typ-2-diabetes | |
| HK40122704A (en) | Methods and compositions for preventing or delaying type 1 diabetes | |
| AU2021900857A0 (en) | Anti-Mollusc Composition (4) | |
| AU2020900932A0 (en) | Anti-Mollusc Composition (3) | |
| CA3286507A1 (en) | Compositions and methods for agri-inputs and uses thereof | |
| HK40089082A (en) | Methods and compositions for the treatment and prevention of type 1 diabetes | |
| AU2024370508A1 (en) | Compounds, compositions and methods thereof | |
| CA3306739A1 (en) | Compounds, compositions and methods thereof | |
| CA3288518A1 (en) | Modified trems, compositions, and related methods thereof | |
| AU2022900746A0 (en) | Anti-Mollusc Composition (5) | |
| CA3308856A1 (en) | Compounds, compositions, and methods | |
| CA3299170A1 (en) | Compounds, compositions, and methods | |
| CA3288852A1 (en) | Compounds, compositions, and methods | |
| CA3277032A1 (en) | Compounds, compositions, and methods | |
| CA3270199A1 (en) | Compounds, compositions and methods | |
| HK40110347A (en) | Stabilized apilimod compositions and uses thereof | |
| HK40122617A (en) | Compounds, compositions, and methods | |
| CA3295097A1 (en) | Compositions and uses thereof | |
| CA3295099A1 (en) | Compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230109 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40095886 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240624 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101ALI20240619BHEP Ipc: A61P 3/10 20060101ALI20240619BHEP Ipc: A61K 39/395 20060101AFI20240619BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250508 |